At Novartis, our purpose is to reimagine medicine to improve and extend people’s lives. We do this by unleashing the power of our associates to deliver transformative innovation, embrace operational excellence, go big on data and digital and build trust with society. This report highlights our progress in advancing these areas to benefit patients and help strengthen our communities and society.
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year
Press Release
Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust
Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved
DNDi will lead Phase II and III clinical development, starting in India with additional trials planned in East Africa
Leishmaniasis, which is transmitted by the sand fly, affects over one billion people; visceral leishmaniasis, the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year
February 3, 2020 - For the seventh consecutive year, Novartis is publishing an annual Novartis in Society ESG report. The report has been prepared in accordance with the GRI Standards: Core option. It supplements the “Build trust with society” section in the 2019 Novartis Annual Review and the 2019 Novartis Annual Report.
Healthcare companies and philanthropies to fund training of thousands of community health workers as part of larger initiative led by Last Mile Health and Living Goods to advance universal health coverage
Press Release
BASEL, SWITZERLAND/NEW YORK, 16 January 2020 /3BL Media/ – Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries, as part of their shared commitment to accelerate universal health coverage. The Health Worker Training Initiative is a three-year investment, generously matched by The Audacious Project, and totals USD $18 million.
The fellowships aim to develop the clinical research skills of early to mid-career scientists in sub-Saharan Africa, specifically on the interaction between poverty-related diseases and noncommunicable diseases
Novartis will provide € 750 000 for at least five fellowships over three years; the EDCTP will match this amount
Novartis invests in the training and support of scientists and researchers from developing countries to help expand their knowledge and expertise and improve their ability to contribute to their local communities
Press Release
The fellowships aim to develop the clinical research skills of early to mid-career scientists in sub-Saharan Africa, specifically on the interaction between poverty-related diseases and noncommunicable diseases
Novartis will provide € 750 000 for at least five fellowships over three years; the EDCTP will match this amount
Novartis invests in the training and support of scientists and researchers from developing countries to help expand their knowledge and expertise and improve their ability to contribute to their local communities
Cette stratégie s’inscrit dans la continuité des Novartis Access Principles, qui visent à intégrer systématiquement des stratégies d’accès dans la manière dont l’entreprise recherche, développe et commercialise ses médicaments dans le monde entier
Une unité récemment formée pour l’Afrique subsaharienne déploiera des approches innovantes pour atteindre davantage de patients, sur l’ensemble de la pyramide des revenus
Novartis se base sur ses activités établies dans le domaine du paludisme, du cancer, de la drépanocytose et des maladies cardiovasculaires, ainsi que sur ses modèles d’entreprises sociales qui ont fait leurs preuves sur ce continent
L’Afrique supporte un quart du fardeau mondial des maladies, mais seuls 3% des professionnels de la santé dans le monde sont basés sur ce continent. Par ailleurs, moins de 1% des dépenses de santé mondiales sont réalisées en Afrique1.
Press Release
Cette stratégie s’inscrit dans la continuité des Novartis Access Principles, qui visent à intégrer systématiquement des stratégies d’accès dans la manière dont l’entreprise recherche, développe et commercialise ses médicaments dans le monde entier
Une unité récemment formée pour l’Afrique subsaharienne déploiera des approches innovantes pour atteindre davantage de patients, sur l’ensemble de la pyramide des revenus
Novartis se base sur ses activités établies dans le domaine du paludisme, du cancer, de la drépanocytose et des maladies cardiovasculaires, ainsi que sur ses modèles d’entreprises sociales qui ont fait leurs preuves sur ce continent
L’Afrique supporte un quart du fardeau mondial des maladies, mais seuls 3% des professionnels de la santé dans le monde sont basés sur ce continent. Par ailleurs, moins de 1% des dépenses de santé mondiales sont réalisées en Afrique1.
Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
15 000 babies are born with sickle cell disease every year in Ghana2
Press Release
Government is already working to accelerate inclusion of the medicine and associated laboratory testing in the National Health Insurance Scheme
Novartis has already delivered more than 20 000 treatments1 and is committed to implementing two clinical trials with novel biologic treatment for sickle cell disease
Partnership includes establishing national treatment guidelines, newborn screening, and centers of excellence for treatment of sickle cell disease; making accessible treatment options available in line with the global standards of care; and using digital technologies to monitor and evaluate patient registration, report real-time data, and help ensure safe large scale roll-out of medicine
15 000 babies are born with sickle cell disease every year in Ghana2
The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health.
Press Release
BASEL, Switzerland, July 8, 2019 /3BL Media/ – The Novartis Foundation is sharpening its focus to concentrate fully on reimagining how data, digital and AI can transform global health. This new mandate builds on 40 years of striving for sustainable impact on health in low-income populations, most recently by focusing on leprosy elimination and cardiovascular health, in addition to digital health.
The Working Group for Primary Healthcare Transformation should complement the government’s efforts to strengthen primary healthcare to achieve Universal Health Coverage (UHC) in Vietnam.
Press Release
HANOI, Vietnam, May 21, 2019 /3BL Media/– A new public-private partnership, comprising the Vietnamese Ministry of Health, and three other founding members, i.e. World Economic Forum (WEF), Harvard Medical School Center for Primary Care and Novartis could transform primary healthcare in Vietnam. As announced by the Vietnamese Ministry of Health, this innovative public-private partnership will help deliver on the Ministry of Health’s objectives the Vietnamese Ministry of Health by strengthening existing primary care demonstration projects in 30 provinces.
